GSK Raises Annual Outlook After Shingles Vaccine Helps Boost Q3 Results
By Scott Kanowsky
Investing.com -- Shares in GlaxoSmithKline (LON: GSK ) moved higher on Wednesday after the drugmaker lifted its full-year earnings and sales outlook following better-than-expected third-quarter results.
The U.K.-based group now expects adjusted operating profit to increase between 15%-17% in 2022, while revenue, excluding pandemic-related sales, is seen rising by 8%-10%.
It had previously guided for an income leap of 13%-15% on revenue growth of 6%-8%.
The move comes after GSK posted turnover of £7.83 billion in the third quarter - an expansion of 9% compared to the corresponding period last year - driven in part by record demand for its Shingrix shingles vaccine.
GSK's specialty medicines division also reported quarterly sales of £2.75 billion, a 24% year-on-year jump, thanks to strong performance of its COVID-19 medicine Xevudy.
Adjusted operating profit during the three months to September 30 climbed by 4% to £2.6 billion.
"We are again raising our full-year guidance and expect good momentum in 2023, further strengthening our confidence in our performance outlooks," said chief executive officer Emma Walmsley in a statement.
She added that the firm is making "good progress" in strengthening its drug pipeline and will continue to "invest in targeted business development."
Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or